Synlogic, Inc. (0A8U.L)

1.8972 +0.0612 (+3.33%) As of 02:31PM BST. Market open.

Synlogic, Inc.

301 Binney Street
Suite 402
Cambridge, MA 02142
United States
617 401 9975
https://www.synlogictx.com

Sector(s): 
Industry: 
Full-time employees: 6

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Timothy K. Lu M.D., Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1981
Dr. James J. Collins Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1967
Ms. Mary Beth Dooley	Head of Finance and Principal Financial Officer & Principal Accounting Officer	N/A	N/A	1981
Mr. Brendan St. Amant	General Counsel & Corporate Secretary	N/A	N/A	N/A
Mr. Ajay Munshi	Vice President of Corporate Development	N/A	N/A	N/A
Mr. Adam J. Thomas	Chief People Officer	N/A	N/A	N/A
Dr. Caroline B. Kurtz Ph.D.	Chief Development Officer	N/A	N/A	N/A
Ms. Molly Harper	Chief Business Officer	N/A	N/A	1977
Dr. Neal Sondheimer M.D., Ph.D.	VP & Head of Clinical	N/A	N/A	N/A
Dr. Mylene Perreault Ph.D.	VP & Head of Research	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Corporate governance

Synlogic, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.